Search Results - "Tuleja, B."

Serum amino-terminal propeptide of type III procollagen in patients with hyperthyroidism or hypothyroidism during therapy by Kucharz, E J, Jurecka-Tuleja, B, Jonderko, G, Marcisz, C

“…Changes in serum amino-terminal type III procollagen propeptide (PIIIPN) and hydroxyproline were compared with indices of thyroid function in 33 patients with…”
Get more information

Markers of tissue response to thyroid hormones in patients with hyperthyroidism or hypothyroidism by Kucharz, E J, Marcisz, C, Jonderko, G, Jurecka-Tuleja, B, Gołab, T, Gina, A R

“…Changes in serum cholesterol and aminoterminal type III procollagen propeptide (PIIIPN) were compared in 33 patients with hyperthyroidism, 16 patients with…”
Get more information

“High” (60 mCi) vs. “low” (30 mCi) activities of 131I as adjuvant treatment for papillary thyroid cancer: the results of a prospective randomized trial by Gawkowska-Suwinska, M., Turska, M., Roskosz, J., Handkiewicz-Junak, D., Tuleja, B., Wygoda, Z., Puch, Z., Jarzab, B.

Get full text

Association of polymorphism of LTalpha and TNF genes with Graves' disease by Kula, D, Jurecka-Tuleja, B, Gubała, E, Krawczyk, A, Szpak, S, Jarzab, M

“…Graves' disease (GD) is an autoimmune disease, which develops on the basis of an interaction between genetic, environmental and endogenous factors. GD is…”
Get more information

Evaluation of bone density in women after thyroid cancer surgery and treatment with suppressive doses of L-thyroxine by Jurecka-Tuleja, B, August, R, Kukulska, A, Bartnikowa, W, Deja, R, Czernik, E, Handkiewicz-Junak, D

“…The aim of this work was to evaluate the degree of bone resorption and incidence of osteoporosis in female postmenopausal patients with differentiated thyroid…”
Get more information

Use of recombinant human TSH for stimulation of iodine radioisotope uptake in metastases of thyroid cancer during therapy with 131I by Roskosz, J, Handkiewicz-Junak, D, Turska, M, Wygoda, Z, Jurecka-Tuleja, B, Jarzab, B

“…The diagnostics with the use of recombinant human TSH for the follow-up of differentiated thyroid carcinoma (DTC) has been already approved. In more than 400…”
Get more information

L-thyroxine therapy in differentiated thyroid carcinoma: criteria for evaluation of TSH suppression by Kowalczyk, P, Roskosz, J, Jurecka-Tuleja, B, Gubała, E, Czernik, E, Jarzab, B

“…Life-time L-thyroxine therapy is obligatory in patients treated for differentiated thyroid carcinoma (DTC) in order to suppress serum TSH. The rationale for…”
Get more information

Evaluation of effects of L-thyroxine therapy in differentiated thyroid carcinoma on the cardiovascular system --prospective study by Matuszewska, G, Roskosz, J, Włoch, J, Jurecka-Tuleja, B, Hasse-Lazar, K, Kowalczyk, P, Jarzab, B

“…Patients with differentiated thyroid carcinoma are treated by thyreoidectomy, followed by radioiodine treatment. A life-time suppressive therapy with…”
Get more information

Early evaluation of treatment effectiveness using 131I iodine radiotherapy in patients with differentiated thyroid cancer by Gawkowska-Suwińska, M, Turska, M, Roskosz, J, Puch, Z, Jurecka-Tuleja, B, Handkiewicz-Junak, D, Wygoda, Z, Jarzab, B

“…This paper presents the preliminary results of a prospective randomized trial on early effectiveness of 30 mCi versus 60 mCi for ablation of thyroid remnants…”
Get more information

Usefulness of determining the blood protein synthesis index in the evaluation of liver damage by Jonderko, G, Bednarczyk-Kałuzny, M, Jurecka-Tuleja, B

“…The purpose of report was the presentation of the variability range of the plasma protein synthesis index (PSI) in dependence on the chronic character of the…”
Get more information